Online inquiry

IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5393MR)

This product GTTS-WQ5393MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD2 gene. The antibody can be applied in Psoriasis, severe chronic plaque research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001328609.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 914
UniProt ID P06729
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5393MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11110MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ12501MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ14758MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ12820MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OMS721
GTTS-WQ12588MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NVS250519
GTTS-WQ3947MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ511MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ4388MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-224818
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW